TY - JOUR
T1 - DNAMethylation Profiles of Ovarian Clear Cell Carcinoma
AU - Cunningham, Julie M.
AU - Winham, Stacey J.
AU - Wang, Chen
AU - Weiglt, Britta
AU - Fu, Zhuxuan
AU - Armasu, Sebastian M.
AU - McCauley, Bryan M.
AU - Brand, Alison H.
AU - Chiew, Yoke Eng
AU - Elishaev, Esther
AU - Gourley, Charlie
AU - Kennedy, Catherine J.
AU - Laslavic, Angela
AU - Lester, Jenny
AU - Piskorz, Anna
AU - Sekowska, Magdalena
AU - Brenton, James D.
AU - Churchman, Michael
AU - DeFazio, Anna
AU - Drapkin, Ronny
AU - Elias, Kevin M.
AU - Huntsman, David G.
AU - Karlan, Beth Y.
AU - Kobel, Martin
AU - Konner, Jason
AU - Lawrenson, Kate
AU - Papaemmanuil, Elli
AU - Bolton, Kelly L.
AU - Modugno, Francesmary
AU - Goode, Ellen L.
N1 - Funding Information:
Memorial Sloan Kettering Cancer Center: This work was funded in part the NCI Cancer Center Core Grant No. P30-CA008748 (MSK: B. Weigelt, J. Konner, and E. Papaemmanuil). B. Weigelt is funded in part by Cycle for Survival and Breast Cancer Research Foundation grants.
Funding Information:
University of Pittsburgh: This project used the UPMC Hillman Cancer Center and Tissue and Research Pathology/Pitt Biospecimen Core shared resource which is supported in part by award P30CA047904 (to F. Modugno).
Funding Information:
This work was supported by Brigham and Women’s Hospital: Foundation for Women’s Cancer as part of the Reproductive Scientist Development Program, Honorable Tina Brozman Foundation, Minnesota Ovarian Cancer Alliance, Deborah and Robert First Family Foundation, Greg and Peggy Strakosch, the Saltonstall Foundation, the Potter Foundation, and the Brigham Ovarian Cancer Research Fund.
Funding Information:
Cedars Sinai Medical Center: The work was supported in part by the American Cancer Society SIOP-06-258-01-COUN (K. Lawrenson).
Funding Information:
University of Pittsburgh: NIH SPORE in ovarian cancer (P50 CA228991, to E. Elishaev and F. Mogduno), the Penn Medicine Translational Center of Excellence in Ovarian Cancer, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Tina’s Wish Foundation, and the Claneil Foundation.
Funding Information:
B. Weigelt reports personal fees from Repare Therapeutics outside the submitted work. Y. Chiew reports grants from National Health and Medical Research Council of Australia and The Cancer Institute NSW grants during the conduct of the study; and grants from AstraZeneca outside the submitted work. C. Gourley reports grants from Nicola Murray Foundation, Aprea, Novartis, and Cancer Research UK during the conduct of the study; grants and personal fees from AstraZeneca, MSD, GSK, Clovis, Nucana, and Tesaro; personal fees from Foundation One, Chugai, and Cor2Ed; grants and personal fees from Sierra Oncology, personal fees from Takeda, grants from BerGenBio and Medannexin outside the submitted work; in addition, C. Gourley has a patent for Molecular Diagnostic Test for Cancer PCT Patent Application No. PCT/US12/40805 pending and issued, a patent for Molecular Diagnostic Test for Cancer PCT Patent Application No. GB2013/053202 issued, and a patent for Molecular Diagnostic Test for Cancer PCT Patent Application No. PCT/GB2015/ 050352 issued. C.J. Kennedy reports grants from National Health and Medical Research Council of Australia and The Cancer Institute New South Wales during the conduct of the study. J.D. Brenton reports grants from Cancer Research UK during the conduct of the study; personal fees from AstraZeneca and GSK outside the submitted work. A. DeFazio reports grants from National Health and Medical Research Council of Australia and The Cancer Institute NSW during the conduct of the study; grants from AstraZeneca outside the submitted work. R. Drapkin reports personal fees from Repare Therapeutics, Boehringer Laboratories, and TwoXAR, Inc. outside the submitted work. D.G. Huntsman is a founder and shareholder of Canexia Health. B.Y. Karlan reports grants from American Cancer Society during the conduct of the study. J. Konner reports advisory board memberships for Merck, AstraZeneca, and Clovis Oncology. E. Papaemmanuil reports other support from Isabl, Inc. outside the submitted work. K.L. Bolton reports grants from Bristol Myers Squbb outside the submitted work. No disclosures were reported by the other authors.
Funding Information:
University of Edinburgh: We thank the Nicola Murray Foundation for their generous support of the laboratory and the NRS Lothian Bioresource volunteers for their participation. We also acknowledge the NHS Trusts and staff for their contribution to this work.
Publisher Copyright:
© 2022 American Association for Cancer Research Inc.. All rights reserved.
PY - 2022/1
Y1 - 2022/1
N2 - Background: Ovarian clear cell carcinoma (OCCC) is a rare ovarian cancer histotype that tends to be resistant to standard platinum-based chemotherapeutics. We sought to better understand the role of DNA methylation in clinical and biological subclassification of OCCC. Methods: We interrogated genome-wide methylation using DNA from fresh frozen tumors from 271 cases, applied nonsmooth nonnegative matrix factorization (nsNMF) clustering, and evaluated clinical associations and biological pathways. Results: Two approximately equally sized clusters that associated with several clinical features were identified. Compared with Cluster 2 (N=137), Cluster 1 cases (N=134) presented at a more advanced stage, were less likely to be of Asian ancestry, and tended to have poorer outcomes including macroscopic residual disease following primary debulking surgery (P < 0.10). Subset analyses of targeted tumor sequencing and IHC data revealed that Cluster 1 tumors showed TP53 mutation and abnormal p53 expression, and Cluster 2 tumors showed aneuploidy and ARID1A/PIK3CA mutation (P < 0.05). Cluster-defining CpGs included 1,388 CpGs residing within 200 bp of the transcription start sites of 977 genes; 38% of these genes (N = 369 genes) were differentially expressed across cluster in transcriptomic subset analysis (P < 10-4). Differentially expressed genes were enriched for six immune-related pathways, including IFNα and IFNg responses (P < 10-6). Conclusions: DNA methylation clusters in OCCC correlate with disease features and gene expression patterns among immune pathways.
AB - Background: Ovarian clear cell carcinoma (OCCC) is a rare ovarian cancer histotype that tends to be resistant to standard platinum-based chemotherapeutics. We sought to better understand the role of DNA methylation in clinical and biological subclassification of OCCC. Methods: We interrogated genome-wide methylation using DNA from fresh frozen tumors from 271 cases, applied nonsmooth nonnegative matrix factorization (nsNMF) clustering, and evaluated clinical associations and biological pathways. Results: Two approximately equally sized clusters that associated with several clinical features were identified. Compared with Cluster 2 (N=137), Cluster 1 cases (N=134) presented at a more advanced stage, were less likely to be of Asian ancestry, and tended to have poorer outcomes including macroscopic residual disease following primary debulking surgery (P < 0.10). Subset analyses of targeted tumor sequencing and IHC data revealed that Cluster 1 tumors showed TP53 mutation and abnormal p53 expression, and Cluster 2 tumors showed aneuploidy and ARID1A/PIK3CA mutation (P < 0.05). Cluster-defining CpGs included 1,388 CpGs residing within 200 bp of the transcription start sites of 977 genes; 38% of these genes (N = 369 genes) were differentially expressed across cluster in transcriptomic subset analysis (P < 10-4). Differentially expressed genes were enriched for six immune-related pathways, including IFNα and IFNg responses (P < 10-6). Conclusions: DNA methylation clusters in OCCC correlate with disease features and gene expression patterns among immune pathways.
UR - http://www.scopus.com/inward/record.url?scp=85122884483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122884483&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-21-0677
DO - 10.1158/1055-9965.EPI-21-0677
M3 - Article
C2 - 34697060
AN - SCOPUS:85122884483
SN - 1055-9965
VL - 31
SP - 132
EP - 141
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 1
ER -